Stock comparison
Regeneron Pharmaceuticals
REGN$80.75BHealthcare Market cap, Sector
SANOFI CONS HEALTHC IND L
SANOFICONR.NS$104.11BHealthcare Market cap, Sector
Overall winner
SANOFI CONS HEALTHC IND L
REGN 07 SANOFICONR.NS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
REGN0wins
7winsSANOFICONR.NS
62C
B78
66C
A89
46D
B83
24F
B77
43F
A91
57D
A86
55D
A85
Side-by-side metrics
| Metric | REGN | SANOFICONR.NS |
|---|---|---|
| Market cap | $80.75B | $104.11B Winner |
| P/E (TTM) | Winner: 16.4x | 44.2x |
| EV/EBIT | Winner: 20.0x | 31.8x |
| ROIC (TTM) | 8.53% | 59.15% Winner |
| Gross margin | Winner: 84.55% | 68.13% |
| Net margin | Winner: 29.65% | 27.35% |
| Revenue CAGR 5y | -2.81% | 27.01% Winner |
| EPS CAGR 5y | -13.35% | 20.67% Winner |
| Debt / Equity | 0.1x | 0.1x Winner |
| Dividend yield | 0.51% | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
REGN leads on
- P/E (TTM)16.4xvs 44.2x+63%
- EV/EBIT20.0xvs 31.8x+37%
- Gross margin84.55%vs 68.13%+19%
- Net margin29.65%vs 27.35%+8%
SANOFICONR.NS leads on
- EPS CAGR 5y20.67%vs -13.35%+165%
- Revenue CAGR 5y27.01%vs -2.81%+110%
- ROIC (TTM)59.15%vs 8.53%+86%
- Debt / Equity0.1xvs 0.1x+25%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.